In diabetic CRC mouse models, GQD treatment increased mucin-degrading Akkermansia muciniphila and SCFA-producers, reduced Fusobacterium load, and was associated with reduced tumor numbers and sizes (particularly in microsatellite-stable CRC, which is often resistant to immunotherapy) [40]. This evidence concerns the gene MUC5AC and colorectal carcinoma.